^
Association details:
| Biomarker: | FGFR2 translocation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Pemazyre (pemigatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Excerpt:
...Objective response rate (ORR) in subjects with FGFR2 translocations based on RECIST v1.1...ORR in subjects with FGF/FGFR alterations other than FGFR2 translocations, all subjects with FGF/FGFR alterations, and subjects negative for FGF/FGFR alterations, based on RECIST v1.1...
Trial ID:
Source:
Title:
Matching Adjusted Indirect Treatment Comparison of FGFR2+ Patients in the FIGHT-202 Trial vs. Patients with Unspecified FGFR2 Status Receiving Standard of Care Treatment
Published date:
04/12/2021
Excerpt:
FGFR2 translocation status....treatment effect for OS and PFS...The weighted HRs ranged from 0.163 (95% CI: 0.099, 0.249) to 0.475 (95% CI: 0.328, 0.657) for OS and from 0.195 (95% CI: 0.117, 0.302) to 0.436 (95% CI: 0.319, 0.599) for PFS….pemigatinib are expected to experience longer time in remission and survival than cholangiocarcinoma patients...
Source:
Title:
Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
Published date:
10/09/2018
Excerpt:
Pts are enrolled into cohort A (FGFR2 translocations), cohort B (other FGF/FGFR genetic alterations [GA]), or cohort C (no FGF/FGFR GAs) and receive oral INCB054828...Of 45 evaluable pts in cohort A, 8 (18%) had a confirmed partial response (PR; 1/8 with unconfirmed complete response) and 26 (58%) had stable disease (3/26 had unconfirmed PRs); the best ORR was 24% (95% CI, 12%–37%). Median PFS was 6.8 months (95% CI, 3.6–9.2 months)....INCB054828 was generally well tolerated and showed preliminary efficacy in pts with previously treated advanced iCCA with FGFR2 translocations.
DOI:
10.1093/annonc/mdy282.139
Trial ID:
